SubHero Banner
Text

Soliris® (eculizumab) – New indication

June 27, 2019 - The FDA announced the approval of Alexion Pharmaceuticals’ Soliris (eculizumab), for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Download PDF